Clinical trial
A Randomized, Single-blind, Placebo-controlled Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine in Healthy Adult Subjects
NCT02419391 is registered in ClinicalTrials.gov with Bavarian Nordic as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Single-blind, Placebo-controlled Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine in Healthy Adult Subjects
- Lead sponsor
- Bavarian Nordic
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 31, 2015
- Completion date
- May 31, 2016
- Enrollment
- 63 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.